Arcus Biosciences, Inc. – NYSE:RCUS
Founder-led company
Arcus Biosciences stock price today
$9.8
-5.46
-35.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Arcus Biosciences stock price monthly change
+1.06%
month
Arcus Biosciences stock price quarterly change
+1.06%
quarter
Arcus Biosciences stock price yearly change
-19.04%
year
Arcus Biosciences key metrics
Market Cap | 1.42B |
Enterprise value | N/A |
P/E | -4.96 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 8.65 |
Price/Book | 1.47 |
PEG ratio | N/A |
EPS | -3.09 |
Revenue | 237M |
EBITDA | -199M |
Income | -231M |
Revenue Q/Q | 480% |
Revenue Y/Y | 176.59% |
Profit margin | -238.39% |
Oper. margin | -250% |
Gross margin | 23.89% |
EBIT margin | -250% |
EBITDA margin | -83.97% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeArcus Biosciences stock price history
Arcus Biosciences stock forecast
Arcus Biosciences financial statements
Average Price Target
$32.5
Potential upside: 231.63%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 29M | -75M | -258.62% |
|---|---|---|---|
| Sep 2023 | 32M | -71M | -221.87% |
| Dec 2023 | 31M | -81M | -261.29% |
| Mar 2024 | 145M | -4M | -2.76% |
| Jun 2023 | 1220000000 | 654M | 53.61% |
|---|---|---|---|
| Sep 2023 | 1191000000 | 671M | 56.34% |
| Dec 2023 | 1095000000 | 633M | 57.81% |
| Mar 2024 | 1293000000 | 586M | 45.32% |
| Jun 2023 | -57M | 26M | 23M |
|---|---|---|---|
| Sep 2023 | -63M | 11M | 6M |
| Dec 2023 | -88M | 28M | 3M |
| Mar 2024 | -2M | -169M | 229M |
Arcus Biosciences alternative data
| Sep 2023 | 500 |
|---|---|
| Oct 2023 | 500 |
| Nov 2023 | 500 |
| Dec 2023 | 500 |
| Jan 2024 | 500 |
| Feb 2024 | 500 |
| Mar 2024 | 577 |
| Apr 2024 | 577 |
| May 2024 | 577 |
| Jun 2024 | 577 |
| Jul 2024 | 577 |
Arcus Biosciences other data
38.13%
-36.29%
of RCUS is owned by hedge funds
112
-83
27.45M
-26.30M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 15238095 | 8979 |
| Feb 2024 | 0 | 85657 |
| Mar 2024 | 0 | 25000 |
| Aug 2024 | 0 | 1357 |
| Dec 2024 | 0 | 201 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | AZOY ALEXANDER officer: Chief Ac.. | Common Stock | 201 | $15.32 | $3,079 | ||
Sale | AZOY ALEXANDER officer: Chief Ac.. | Common Stock | 1,357 | $14.97 | $20,314 | ||
Sale | JARRETT JENNIFER officer: Chief Operating Officer | Common Stock | 11,551 | $17.55 | $202,720 | ||
Sale | JARRETT JENNIFER officer: Chief Operating Officer | Common Stock | 12,153 | $17.84 | $216,810 | ||
Sale | JARRETT JENNIFER officer: Chief Operating Officer | Common Stock | 1,296 | $18.62 | $24,132 | ||
Sale | JARRETT JENNIFER officer: Chief Operating Officer | Common Stock | 34,070 | $20.11 | $685,148 | ||
Sale | JAEN JUAN C. officer: President | Common Stock | 23,132 | $20.1 | $464,953 | ||
Sale | JARRETT JENNIFER officer: Chief Operating Officer | Common Stock | 24,555 | $20.07 | $492,819 | ||
Sale | JAEN JUAN C. officer: President | Common Stock | 3,900 | $20.06 | $78,234 | ||
Purchase | GILEAD SCIENCES, INC. 10 percent owner | Common Stock | 15,238,095 | $21 | $319,999,995 |
| Patent |
|---|
Application Filling date: 11 Mar 2020 Issue date: 4 Aug 2022 |
Application Filling date: 5 Jun 2020 Issue date: 28 Jul 2022 |
Application Filling date: 27 Mar 2020 Issue date: 7 Jul 2022 |
Application Filling date: 22 Oct 2021 Issue date: 12 May 2022 |
Grant Filling date: 17 Nov 2017 Issue date: 8 Mar 2022 |
Application Filling date: 1 Jun 2021 Issue date: 3 Mar 2022 |
Application Filling date: 12 Dec 2019 Issue date: 3 Mar 2022 |
Application Filling date: 15 Nov 2019 Issue date: 20 Jan 2022 |
Grant Filling date: 16 May 2018 Issue date: 11 Jan 2022 |
Application Filling date: 16 Jun 2021 Issue date: 23 Dec 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2021 7 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Ms. Jennifer Jarrett M.B.A. (1971) Chief Operating Officer & Director | $603,170 |
| Dr. Terry J. Rosen Ph.D. (1960) Co-Founder, Chairman & Chief Executive Officer | $326,820 |
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI +
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025
Arcus: Excellent Pipeline And Collaborations, Cash Runway
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Arcus Biosciences: Anti-TIGIT Therapy On Track With ARC-7 Results
-
What's the price of Arcus Biosciences stock today?
One share of Arcus Biosciences stock can currently be purchased for approximately $9.8.
-
When is Arcus Biosciences's next earnings date?
Unfortunately, Arcus Biosciences's (RCUS) next earnings date is currently unknown.
-
Does Arcus Biosciences pay dividends?
No, Arcus Biosciences does not pay dividends.
-
How much money does Arcus Biosciences make?
Arcus Biosciences has a market capitalization of 1.42B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.46% to 117M US dollars.
-
What is Arcus Biosciences's stock symbol?
Arcus Biosciences, Inc. is traded on the NYSE under the ticker symbol "RCUS".
-
What is Arcus Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Arcus Biosciences?
Shares of Arcus Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Arcus Biosciences's key executives?
Arcus Biosciences's management team includes the following people:
- Ms. Jennifer Jarrett M.B.A. Chief Operating Officer & Director(age: 54, pay: $603,170)
- Dr. Terry J. Rosen Ph.D. Co-Founder, Chairman & Chief Executive Officer(age: 65, pay: $326,820)
-
Is Arcus Biosciences founder-led company?
Yes, Arcus Biosciences is a company led by its founder Dr. Terry J. Rosen Ph.D..
-
How many employees does Arcus Biosciences have?
As Jul 2024, Arcus Biosciences employs 577 workers.
-
When Arcus Biosciences went public?
Arcus Biosciences, Inc. is publicly traded company for more then 7 years since IPO on 15 Mar 2018.
-
What is Arcus Biosciences's official website?
The official website for Arcus Biosciences is arcusbio.com.
-
Where are Arcus Biosciences's headquarters?
Arcus Biosciences is headquartered at 3928 Point Eden Way, Hayward, CA.
-
How can i contact Arcus Biosciences?
Arcus Biosciences's mailing address is 3928 Point Eden Way, Hayward, CA and company can be reached via phone at +51 06946200.
-
What is Arcus Biosciences stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Arcus Biosciences in the last 12 months, the avarage price target is $32.5. The average price target represents a 231.63% change from the last price of $9.8.
Arcus Biosciences company profile:
Arcus Biosciences, Inc.
arcusbio.comExchange:
NYSE
Full time employees:
577
Industry:
Biotechnology
Sector:
Healthcare
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
3928 Point Eden Way
Hayward, CA 94545
Hayward, CA 94545
CIK: 0001724521
ISIN: US03969F1093
CUSIP: 03969F109
